Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho.
Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC, Greninger AL. · 2020
Read Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. by Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC, Greninger AL. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7383515.txt.
Description
Bryan and co-authors evaluate a commercial COVID-19 antibody test in the Journal of Clinical Microbiology. Slow diagnostic rollout in the United States left many early infections untested, so blood tests had to reconstruct who had been infected. The team checked the Abbott Architect IgG assay in three patient groups, and measured past infection around Boise, Idaho.
On blood drawn before the pandemic, the test wrongly flagged only 1 of 1,020 samples, a specificity of 99.90 percent. On samples from confirmed patients, sensitivity reached 100 percent when blood was taken at least 17 days after symptoms began, at the right cutoff. Earlier samples read less reliably. The study gives labs hard performance numbers for a widely used test.
Catalog record
| CREATOR | Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC, Greninger AL. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |